<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a previous study, we showed that the high level of protein tyrosine phosphorylation present in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> containing an anaplastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> kinase (ALK) can be demonstrated in routinely processed paraffin tissue sections using immunolabelling techniques </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we investigated whether oncogenic tyrosine kinase activation also occurs in other categories of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by staining 145 cases of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> covering those <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with a range of different subtypes including those with morphological similarity to ALK-positive anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Twelve cases of the borderline malignant disorder <z:e sem="disease" ids="C0206182" disease_type="Neoplastic Process" abbrv="lyp">lymphomatoid papulosis</z:e> were also studied </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty seven of the 28 cases of ALK-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> showed the extensive cytoplasmic labelling for phosphotyrosine in the neoplastic cells </plain></SENT>
<SENT sid="4" pm="."><plain>The remaining case containing moesin-ALK exhibited membrane-associated phosphotyrosine expression </plain></SENT>
<SENT sid="5" pm="."><plain>There was no nuclear phosphotyrosine labelling in any of the ALK-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>, even though ALK was present within the cell nuclei in 23 of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Variable degrees of phosphotyrosine labelling, usually membrane-restricted, were observed in 7/40 cases of ALK-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>, 9/29 cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3/6 cases of mediastinal B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 2/7 cases of Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3/6 cases of peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> unspecified, 4/6 cases of B-cell <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, 2/6 cases of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 2/12 cases of <z:e sem="disease" ids="C0206182" disease_type="Neoplastic Process" abbrv="lyp">lymphomatoid papulosis</z:e> studied </plain></SENT>
<SENT sid="7" pm="."><plain>However none of these phosphotyrosine-positive cases showed the strong cytoplasmic labelling comparable to that seen in ALK-positive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that activation of a tyrosine kinase is probably not a major oncogenic event in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> other than ALK-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> </plain></SENT>
</text></document>